

## THE ASSOCIATION BETWEEN TAMOXIFEN AND THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA: CASE REPORT AND LITERATURE REVIEW

Calvin H.L. Law, MD; Véd R. Tandan, MD, MSc

Tamoxifen has become one of the most widely used drugs in the treatment of breast cancer, and concerns about its long-term safety and efficacy are being raised. Investigations in rats have suggested an association between the administration of tamoxifen and the development of hepatocellular carcinoma. However, no studies to date have demonstrated an increased incidence of hepatocellular carcinoma in women treated with tamoxifen. In the case reported, a 56-year-old woman presented with hepatocellular tumours after 6 years of tamoxifen therapy for breast cancer. The patient had no other risk factors for the development of hepatocellular carcinoma. She underwent successful resection of the lesions, and subsequent pathological studies confirmed hepatocellular carcinoma with a trabecular growth pattern similar to the histologic pattern seen in tamoxifen-induced hepatocellular carcinoma occurring in rat models.

Le tamoxifène est devenu un des médicaments les plus répandus dans le traitement du cancer du sein et sa sécurité et son efficacité à long terme préoccupent. Des études réalisées sur des rats indiquent qu'il y a peut-être un lien entre l'administration de tamoxifène et l'apparition du carcinome hépatocellulaire. Aucune étude n'a toutefois démontré jusqu'à maintenant d'incidence accrue du carcinome hépatocellulaire chez les femmes traitées au tamoxifène. Dans le cas qui fait l'objet du rapport, une femme âgée de 56 ans avait des tumeurs hépatocellulaires après avoir suivi pendant six ans un traitement au tamoxifène contre le cancer du sein. La patiente ne présentait aucun autre facteur de risque d'apparition du carcinome hépatocellulaire. Elle a subi une résection réussie des lésions et des analyses pathologiques subséquentes ont confirmé la présence d'un carcinome hépatocellulaire avec excroissance trabéculaire semblable à l'évolution histologique constatée dans les cas de carcinome hépatocellulaire provoqué par le tamoxifène chez des modèles murins.

Tamoxifen, a nonsteroidal triphenylethylene derivative having a chemical structure similar to diethylstilbestrol, is currently used as an antiestrogen in the treatment of breast cancer as primary and adjuvant therapy. However, several recent studies showed that women treated with tamoxifen had a

lower incidence of second or contralateral breast cancer.<sup>1-3</sup> These data prompted trials of tamoxifen as a chemopreventive agent in women at risk for the development of breast cancer.<sup>4</sup> A 2-year safety evaluation study conducted by the manufacturer of tamoxifen has shown that liver tumours develop in rats exposed to tamoxifen.<sup>5</sup>

More recent studies continue to confirm the hepatoproliferative and carcinogenic properties of tamoxifen in rats.<sup>6-8</sup> A recent review of 9 population-based cancer registries in the United States attempted to determine if there has been any change in the incidence of hepatocellular carcinoma since 1977, the year that the US Federal

*From the Department of Surgery, St. Joseph's Hospital, McMaster University, Hamilton, Ont.*

*Accepted for publication Sept. 2, 1998.*

**Correspondence to:** Dr. Véd R. Tandan, St. Joseph's Hospital, G815 – 50 Charlton Ave. E, Hamilton ON L8N 4A6; fax 905 521-6154, tandanv@fhs.mcmaster.ca

© 1999 Canadian Medical Association (text and abstract/résumé)

Drug Administration licensed tamoxifen for use.<sup>9</sup> This study did not show any increase in the incidence of hepatocellular carcinoma in this group; however, the results can be questioned owing to a number of confounding factors. We present a case in which hepatocellular carcinoma developed in a patient who had been on long-term tamoxifen therapy.

### CASE REPORT

A 56-year-old woman who was undergoing radiologic investigation of recurrent pneumothoraces was found to have 2 masses in the liver: a 9.0-cm mass in the lateral segment and a 1.5-cm mass in the caudate lobe. Her  $\alpha$ -fetoprotein level was elevated to 4860  $\mu\text{g/L}$  and a subsequent needle biopsy was suspicious for hepatocellular carcinoma. Her history included a bilateral lumpectomy and left axillary node dissection for invasive ductal carcinoma of the breast 9 years earlier. From 1989 to 1995 she received tamoxifen (20 mg/d) as adjuvant treatment. She also had undergone cholecystectomy, hysterectomy and a hiatus hernia repair. She did not have any history of oral contraceptive use, hepatitis, blood transfusions or significant alcohol intake. Her hepatic synthetic function was normal, and hepatitis B and C serologic findings were negative. Intraoperative ultrasonography confirmed that there were no other lesions in the liver, and an uncomplicated left lateral segment and caudate lobe resection was performed. She was discharged from hospital on the fifth postoperative day. Histologic examination of the resected specimen confirmed hepatocellular carcinoma in a trabecular growth pattern. The surrounding liver was entirely normal grossly and histologically. At her 6-month follow-up, she was doing well with no radiologic or laboratory evidence of recurrence.

### DISCUSSION

Tamoxifen is one of the most widely used chemotherapeutic agents in the world. Its success in increasing survival when used as an adjuvant agent as well as its tendency to reduce the incidence of contralateral breast cancer has inspired the hope that it will act as a chemopreventive agent in women considered to be at high risk for breast cancer. The National Adjuvant Surgical Breast and Bowel Project (NSABP) has recently published the results of the Breast Cancer Prevention Trial (P-1), reporting a decreased incidence of breast cancer in women with significant risk factors while taking tamoxifen.<sup>10</sup> Other clinical trials are also under way,<sup>4</sup> but the actual reduction in risk of breast cancer may require up to 5 years of tamoxifen therapy.

Animal studies have been limited mainly to rats, in which tamoxifen has been confirmed as a factor in the development of hepatocellular carcinoma. Studies show that tamoxifen given orally results in the formation of DNA adducts. A high number of adducts are found in those rats in which hepatocellular carcinoma subsequently develops, suggesting a causal relationship.<sup>6-8</sup> Several interesting observations were noted by Carthew and associates.<sup>7</sup> First, they found that DNA adduct formation is not only dose-dependent but also time-dependent in the rat. Previous criticisms of rat studies focused on the higher relative doses used in rats than in humans. Second, they noted that there was a significant difference in biologic response between strains of rats. Fischer rats did not undergo as much liver proliferation in response to tamoxifen at the same time periods as did corresponding Wistar and Lewis rats. In addition, they did not progress from foci of proliferation to carcinoma

during the study period. These data suggest a possible pharmacogenetic component to tamoxifen-induced hepatocellular carcinoma.

Hepatocellular carcinoma can have a wide variety of histologic patterns ranging from trabecular, sclerosing and fibrolamellar to the arrangement of compact sheets as seen in the anaplastic type. In the rat models, the trabecular pattern of hepatocellular carcinoma was noted uniformly in the tamoxifen-induced tumours.<sup>6</sup> Histologic examination of the tumours from the patient in this report also revealed the trabecular pattern.

In general, hepatocellular carcinoma is relatively uncommon in humans. In Canada, the age-adjusted rates per 100 000 people are 2.0 for men and 0.8 for women.<sup>11</sup> Mühlemann and colleagues<sup>9</sup> reviewed the breast cancer population in 9 registries in the United States, looking for evidence of an increased rate of hepatocellular carcinoma in those patients who had been on long-term tamoxifen since its introduction in 1977. Unfortunately, the use of tamoxifen and the dose of tamoxifen were not directly analysed in that study. Instead a subgroup of women with breast cancer and older than 50 years were examined, this being the group most likely to have received tamoxifen. There is no way to know exactly what proportion of women in these groups actually received tamoxifen after 1977. In addition, there was no accounting of women who presented with "hepatic metastases" without a histologically proven diagnosis. It may also be too early to see any longer term hepatic effects from previous tamoxifen use.

Current data from larger trials involving tamoxifen have not documented any increase in the incidence of hepatocellular carcinoma to date. The combined results of the Stock-

holm Trial, the Danish Breast Cancer Group Trial and the South-Swedish Trial, involving 4914 patients, did not demonstrate any significant difference in the incidence of hepatocellular carcinoma between the tamoxifen and control groups.<sup>12</sup> In those studies, 4 patients in the tamoxifen group and 3 patients in the control group had hepatocellular carcinoma. Data from the NSABP Protocol B-14,<sup>13</sup> involving 2843 patients, did not report any cases of hepatocellular carcinoma, and neither did the Manchester study, which involved 961 patients.<sup>14</sup> Moreover, the recent BCPT did not report any case of hepatocellular carcinoma.<sup>10</sup>

There is concern that cases of hepatocellular carcinoma in these trials may have been misinterpreted as hepatic metastases from the known breast carcinoma without histologic confirmation. Unfortunately, data regarding the incidence of hepatic metastases in these large trials is incomplete. The Danish Breast Cancer Group Trials (DBCG 77 C and DBCG 82 C) did not report the number of distant metastases or the location of distant treatment failures.<sup>15</sup> The Stockholm Breast Cancer Group Trials showed no statistical difference in the number of distant metastases among patients treated with adjuvant radiotherapy (103 of 311 patients) versus adjuvant tamoxifen (141 of 395 patients).<sup>16</sup> The NSABP Protocol B-14 also showed no difference in the number of "other distant recurrences" between placebo (19 of 1326) and tamoxifen (19 of 1318).<sup>17</sup> Information regarding the location of distant recurrence or the number of new liver lesions in each group was not available in any of the above studies. Whether histopathological confirmation of the distant recurrence was made is not known either.

In humans, a single previous case report of hepatocellular carcinoma de-

veloping after a diagnosis of breast cancer and initiation of tamoxifen has been reported by Johnstone and associates.<sup>18</sup> However, the diagnosis of hepatocellular carcinoma was made only 6 months after the initiation of adjuvant therapy for her breast cancer and the patient was also taking numerous chemotherapeutic agents carrying their own risk of carcinogenesis.

There has been concern from published reports that oral contraceptive users had a relative risk of 2.6 for hepatocellular carcinoma and increasing risk with long-term use.<sup>19</sup> The concern for tamoxifen related to the fact that although the drug had mainly antiestrogenic effects for the breast, there was some evidence of estrogenic properties.<sup>20</sup>

#### SUMMARY

Since tamoxifen has been established as a successful drug in the fight against breast cancer, concern has arisen that it may induce other tumours. The development of hepatocellular carcinoma reported in rat experiments is alarming. Although these findings do not necessarily translate directly to human effects, they may serve as a warning for maintained vigilance in the investigation of tamoxifen as a carcinogen. Currently, none of the larger trials utilizing tamoxifen has demonstrated any increase in the incidence of hepatocellular carcinoma. However, it is unclear whether a biopsy has been taken in patients with presumed hepatic metastases to rule out hepatocellular carcinoma. The case presented here demonstrates the development of hepatocellular carcinoma in a patient on tamoxifen who had no other risk factor for the development of the disease. Although a mechanism linking tamoxifen and hepatocellular carcinoma has yet to be discovered, future studies may help to

identify a subgroup of patients who may be susceptible to a tamoxifen-induced hepatocellular carcinoma.

#### References

1. Cuzick J, Wang DY, Bulbrook RD. The prevention of breast cancer. *Lancet* 1986;1:83-6.
2. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. *J Natl Cancer Inst* 1991;83:1450-9.
3. Powles TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. *Lancet* 1992;340:1145-7.
4. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, et al. Prevention of breast cancer with tamoxifen — an update on the Royal Marsden Hospital pilot programme. *Eur J Cancer* 1990;26:680-4.
5. Barnhart ER, editor. ICI Pharma Nolvadex. In: *Physician's desk reference*. 45th ed. Oradell (NJ): Medical Economics; 1991. p. 1070-2.
6. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltneberg OP, Imondi AR, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female CrI:CD(BR) rats. *Cancer Res* 1993;53:4534-41.
7. Carthew P, Rich KJ, Martin EA, De Matteis F, Lim CK, White INH, et al. DNA damage as assessed by <sup>32</sup>P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. *Carcinogenesis* 1995; 16(6):1299-1304.
8. Phillips DH, Potter GA, Horton MN, Hewer A, Crofton-Sleigh C, Jarman M, et al. Reduced genotoxicity of [D<sub>5</sub>-ethyl]-tamoxifen implicates alpha hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. *Carcinogenesis* 1994;15(8):1487-92.
9. Mühlemann K, Cook LS, Weiss NS. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamox-

ifen in 1977. *Breast Cancer Res Treat* 1994;30:201-4.

10. Fisher B, Costantino JP, Wickerham, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998;90(18):1371-88.

11. World Health Organization. *World health statistics annual 1994*. Geneva: The Organization; 1995. p. B-14.

12. Rutqvist LE, Johansson H, Signomk-lao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. *J Natl Cancer Inst* 1995;87(9):645-51.

13. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *J Natl Cancer Inst* 1994;86(7):527-37.

14. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. *J Natl Cancer Inst Monogr* 1992;11: 121-5.

15. Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. *Acta Oncol* 1988; 27:699-705.

16. Rutqvist L, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Radiotherapy, chemotherapy and tamoxifen as adjuncts to surgery in early breast cancer. A summary of three randomized trials. *Int J Rad Oncol Biol Phys* 1989;16:629-39.

17. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. *N Engl J Med* 1989;320(8): 479-84.

18. Johnstone AJ, Sarkar TK, Hussey JK. Primary hepatocellular carcinoma in a patient with breast carcinoma. *Clin Oncol (R Coll Radiol)* 1991;3(3):180-1.

19. Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. *Prev Med* 1991;20:38-46.

20. Jordan VC. The role of tamoxifen in the treatment and prevention of breast cancer. *Curr Probl Cancer* 1992;16 (3):129-76.

**NOTICE OF CHANGE OF ADDRESS  
AVIS DE CHANGEMENT D'ADRESSE**

To ensure that you continue to receive the *Canadian Journal of Surgery* without interruption, please fill in and mail this form before you move.

Avant de déménager, assurez-vous de recevoir sans interruption le *Journal canadien de chirurgie* en complétant et en expédiant le formulaire suivant.

Please print / En lettres moulées, svp

Name / Nom. ....

Old address / Ancienne adresse .....

New address / Nouvelle adresse .....

Date effective / Date en vigueur .....

Subscribers please mail to: Member Service Centre, Canadian Medical Association, 1867 Alta Vista Dr., Ottawa ON K1G 3Y6.

Abonnés, veuillez expédier au : Centre des services aux membres, Association médicale canadienne, 1867, prom Alta Vista, Ottawa ON K1G 3Y6.

US address changes / Envoyer les changements d'adresse américaine à : International Media Services (IMS) of New York, 100 Walnut St., #3, PO Box 1518, Champlain NY 12919-1518.